Anti‐MUC1 aptamer: A potential opportunity for cancer treatment
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Mucin 1 (MUC1) is a protein usually found on the apical surface of most normal secretory epithelial cells. However, in most adenocarcinomas, MUC1 is overexpressed, so that it not only appears over the entire cell surface, but is also shed as MUC1 fragments into the blood stream. These phenomena pinpoint MUC1 as a potential target for the diagnosis and treatment of cancer; consequently, interest has increased in MUC1 as a molecular target for overcoming cancer therapy challenges. MUC1 currently ranks second among 75 antigen candidates for cancer vaccines, and different antibodies or aptamers against MUC1 protein are proving useful for tracing cancer cells in the emerging field of targeted delivery. The unique properties of MUC1 aptamers as novel targeting agents, and the revolutionary role that MUC1 now plays in cancer therapy, are the focus of this review. Recent advancements in MUC1‐targeted cancer therapy are also assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of chitin and chitosan applications
Ravi Kumar, M. N. V. (2000) · Reactive and Functional Polymers · doi:10.1016/s1381-5148(00)00038-9 · Cited by 6,009
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
“Few patient complications, fast recovery and little damage to surrounding healthy tissue are main advantages of applying this treatment [107,108].”
BackgroundSelf-citationAram, E., Moeni, M., Abedizadeh, R., Sabour, D., Sadeghi-Abandansari, H., Gardy, J., & Hassanpour, A. (2022) · Nanomaterials · doi:10.3390/nano12203567 · Cited by 66
Kotha, R., Fernandes, G., Nikam, A. N., Kulkarni, S., Pandey, A., Pandey, S., & Mutalik, S. (2020) · Materials Science and Technology · doi:10.1080/02670836.2020.1832323 · Cited by 17
“S2 .2 a 25-base oligonucleotide was one of the widely employed MUC1 aptamers which show high specificity and affinity [172].”
Background
Metadata
- Authors
- Nabavinia, M. S., Gholoobi, A., Charbgoo, F., Nabavinia, M., Ramezani, M., & Abnous, K.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2017-07-31
- Volume
- 37
- Issue
- 6
- Pages
- 1518-1539
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2740207635
- Cited by
- 135
- References
- 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.